The thesis

RCM Technologies sells engineering, specialty health care, and life sciences staffing and solutions across North America and Serbia. Revenue grew 20% year over year at a 26.9% gross margin, yet the stock trades at 13.9 times earnings. Analysts rate it a buy while our conviction model scores it 8 out of 100, dormant. That gap is the tension: the fundamentals compound quietly while the market treats the name as asleep, and the reshoring and transport theme it sits inside has not yet activated.

Why now

The post-election Blue Wave sent the Dow up 1,200 points and rotated capital toward domestic industrials, the exact basket where RCM's reshoring exposure lives. A 20% growth rate at a 13.9 multiple means the market is paying nothing for that acceleration if the rotation reaches it.

What to watch

Watch quarterly revenue growth against the 20% pace and gross margin against 26.9% to confirm the operational story holds. Watch rotation signals into industrials and reshoring names, plus any move in the multiple off 13.9 times earnings, as the marker that the market has noticed.

Key risks

A dormant conviction score means no capital is confirming the thesis, so the stock can stay cheap despite growth. Net margin of 5.1% leaves almost no cushion if staffing demand softens or pricing slips. If the risk-on rotation stays inactive, the reshoring catalyst never arrives and the buy rating carries the stock nowhere.

Theme exposure